“and a full year adjusted operating profit margin of approximately 29%.”

In context

“e our differentiated diagnostics portfolio. During the event, we highlighted how DBS-driven innovation and commercial execution have meaningfully improved the growth and margin profile of our diagnostics franchise over the last several years. We also talked about how we are uniquely positioned for long term growth opportunities in high-value, high-need areas such as neurodegenerative diseases, infectious diseases and oncology. And if you haven't had the chance to see the replay, I'd encourage you to watch it on our Investor Relations website. Now, let's briefly look ahead at expectations for the fourth quarter and the full year 2024. For the full year 2024, there is no change to our previous guidance and as a reminder, we anticipate a core revenue decline in low single-digit percent range and a full year adjusted operating profit margin of approximately 29%. In the fourth quarter, we expect core revenue to decline in the low single-digit percent range. Additionally, we expect the fourth quarter adjusted operating profit margin of approximately 30%. So to wrap up, we're pleased with our better-than-expected third quarter performance and expect the trends we're seeing today to continue into Q4. Our team's commitment to executing and innovating with the Danaher Business System enabled us to deliver strong results while continuing to accelerate growth initiatives across the portfolio. Our third quarter results also reflect the unique positioning of Danaher today. We have an outstanding group of businesses that serve attractive end markets with favorable long term, secular growth drivers. We're further enhancing our portfolio and competitive advan”